Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nautilus Biotechnology, Inc.NAUT · Entity 6679 | Senior VP, Operations | September 23, 2024 | September 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nautilus Biotechnology, Inc.
Report date September 23, 2024 · Filed September 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-09-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-23 · Exercise / conversion · Acquired 47,031 · Balance 47,031 Row 2 · 2024-09-23 · Sale · Disposed 47,031 · Balance 0 F1: Represents the weighted average share price of an aggregate total of 47,031 shares purchased in the price range of $2.80 to $3.02 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2030-01-30 | Direct | 353,337 |
Reported balance
After 2024-09-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-23 · Exercise / conversion · Disposed 47,031 · Balance 353,337 F2: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement date is January 21, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average share price of an aggregate total of 47,031 shares purchased in the price range of $2.80 to $3.02 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement date is January 21, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2024 Filed Sep 25, 2024 22:29 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,031 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001808805-24-000067 · wk-form4_1727303354.xml · derivative · entry 3 Godwin Mary E. · CIK 0001439716 · Senior VP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,337 Underlying: Common Stock · 47,031 shares Expires 2030-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement date is January 21, 2020. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 22:29 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | SaleCommon Stock | 47,031 | $2.87 | $134,743.82 |
DisclosureSEC source: 0001808805-24-000067 · wk-form4_1727303354.xml · nonDerivative · entry 2 Godwin Mary E. · CIK 0001439716 · Senior VP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average share price of an aggregate total of 47,031 shares purchased in the price range of $2.80 to $3.02 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 22:29 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | Exercise / conversionCommon Stock | 47,031 | $0.46 | $21,634.26 |
DisclosureSEC source: 0001808805-24-000067 · wk-form4_1727303354.xml · nonDerivative · entry 1 Godwin Mary E. · CIK 0001439716 · Senior VP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 22:32 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001808805-24-000065 · wk-form4_1726698721.xml · derivative · entry 3 Godwin Mary E. · CIK 0001439716 · Senior VP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,368 Underlying: Common Stock · 35,000 shares Expires 2030-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement date is January 21, 2020. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 22:32 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | SaleCommon Stock | 35,000 | $2.85 | $99,869.00 |
DisclosureSEC source: 0001808805-24-000065 · wk-form4_1726698721.xml · nonDerivative · entry 2 Godwin Mary E. · CIK 0001439716 · Senior VP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average share price of an aggregate total of 35,000 shares purchased in the price range of $2.80 to $2.99 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 22:32 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | Exercise / conversionCommon Stock | 35,000 | $0.46 | $16,100.00 |
DisclosureSEC source: 0001808805-24-000065 · wk-form4_1726698721.xml · nonDerivative · entry 1 Godwin Mary E. · CIK 0001439716 · Senior VP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:23 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001808805-24-000010 · wk-form4_1709673794.xml · derivative · entry 1 Godwin Mary E. · CIK 0001439716 · Senior VP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 22:18 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001808805-23-000029 · wf-form4_167770909041820.xml · derivative · entry 1 Godwin Mary E. · CIK 0001439716 · Senior VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 01:15 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001808805-22-000087 · wf-form4_165957568676746.xml · derivative · entry 1 Godwin Mary E. · CIK 0001439716 · Senior VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-08-03 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is July 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.